Cosciens Biopharma (TSX:CSCI) Debt-to-Equity: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CSCI Cosciens Biopharma Inc TSX:CSCI
54 GF Score
Price C$7.10
GF Value C$9.76
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Debt-to-Equity?

Cosciens Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was C$0.00 Mil. Cosciens Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was C$0.00 Mil. Cosciens Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was C$0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cosciens Biopharma's Debt-to-Equity or its related term are showing as below:

TSX:CSCI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.1   Max: 0.56
Current: 0.56

During the past 13 years, the highest Debt-to-Equity Ratio of Cosciens Biopharma was 0.56. The lowest was 0.03. And the median was 0.10.

TSX:CSCI's Debt-to-Equity is ranked worse than
77.79% of 968 companies
in the Biotechnology industry
Industry Median: 0.16 vs TSX:CSCI: 0.56

Cosciens Biopharma  (TSX:CSCI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cosciens Biopharma Debt-to-Equity Related Terms

Cosciens Biopharma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Debt-to-Equity Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.08 0.08 0.18 0.56

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.32 0.43 0.56 N/A

TSX:CSCI vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Debt-to-Equity falls into.


TSX:CSCI
54GF Score
Cosciens Biopharma Inc TSX:CSCI
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cosciens Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.297 + 2.668) / 5.3
=0.56

Cosciens Biopharma's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of C$7.10 is trading 27.3% below its estimated GF Value™ of C$9.76. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for TSX:CSCI:

  • Debt-to-Equity: N/A
  • GF Value™: C$9.76 vs. price of C$7.10 (27.3% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges CSCIF:USAET8:Germany
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
54GF Score

Get the complete analysis for TSX:CSCI

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$7.10
Price
C$9.76
GF Value